Piper Sandler reiterated their buy rating on shares of Crispr Therapeutics (NASDAQ:CRSP) in a research note released on Thursday, TipRanks reports. They currently have a $104.00 target price on the stock.

CRSP has been the subject of a number of other research reports. Chardan Capital reiterated a buy rating and issued a $72.50 price target on shares of Crispr Therapeutics in a report on Thursday. Roth Capital boosted their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. ValuEngine lowered Crispr Therapeutics from a hold rating to a sell rating in a report on Friday, January 3rd. Oppenheimer boosted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a report on Monday, November 25th. Finally, William Blair reiterated a buy rating on shares of Crispr Therapeutics in a report on Thursday. Three analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the company’s stock. Crispr Therapeutics presently has a consensus rating of Buy and an average price target of $78.29.

Shares of NASDAQ CRSP traded down $2.32 during trading hours on Thursday, reaching $55.80. The stock had a trading volume of 1,623,146 shares, compared to its average volume of 1,113,728. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -121.30 and a beta of 3.25. The business’s fifty day moving average price is $57.85 and its two-hundred day moving average price is $53.01. Crispr Therapeutics has a 52-week low of $30.75 and a 52-week high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $1.19. The firm had revenue of $77.00 million during the quarter, compared to analyst estimates of $39.08 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Crispr Therapeutics’s quarterly revenue was up 76900.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.92) earnings per share. Equities research analysts anticipate that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.

In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. 21.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of CRSP. Nikko Asset Management Americas Inc. lifted its holdings in Crispr Therapeutics by 48.4% during the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after buying an additional 906,006 shares during the period. Orbimed Advisors LLC purchased a new stake in Crispr Therapeutics during the third quarter worth $21,167,000. FMR LLC lifted its holdings in shares of Crispr Therapeutics by 71.8% during the 4th quarter. FMR LLC now owns 952,369 shares of the company’s stock valued at $58,004,000 after purchasing an additional 398,012 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Crispr Therapeutics by 904.0% during the 4th quarter. Renaissance Technologies LLC now owns 394,564 shares of the company’s stock valued at $24,031,000 after purchasing an additional 355,264 shares during the last quarter. Finally, ARK Investment Management LLC lifted its holdings in shares of Crispr Therapeutics by 6.3% during the 4th quarter. ARK Investment Management LLC now owns 2,956,635 shares of the company’s stock valued at $180,074,000 after purchasing an additional 174,495 shares during the last quarter. Institutional investors own 50.01% of the company’s stock.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: What are municipal bonds?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.